Fate Therapeutics/FATE

$4.82

-4.37%
-
1D1W1MYTD1YMAX

About Fate Therapeutics

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.

Ticker

FATE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

John Wolchko

Employees

181

Headquarters

San diego, United States

FATE Metrics

BasicAdvanced
$596.42M
Market cap
-
P/E ratio
-$1.63
EPS
1.74
Beta
-
Dividend rate
$596.42M
1.74499
$8.83
$1.63
2.82M
8.481
-26.56%
-37.76%
-30.4%
9.388
1.411
1.619
-34.03%
43.83%
26.43%

What the Analysts think about FATE

Analyst Ratings

Majority rating from 20 analysts.
Hold

Price Targets

Average projection from 15 analysts.
61.83% upside
High $12.00
Low $5.00
$4.82
Current price
$7.80
Average price target

FATE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2,756.25% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$1.6M
-15.79%
Net income
$-44.1M
-2.22%
Profit margin
-2,756.25%
16.12%

FATE Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 13.9%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.19
-$0.54
-$0.46
-$0.45
-
Expected
-$0.62
-$0.59
-$0.57
-$0.52
-$0.49
Surprise
-69.5%
-8.22%
-19.28%
-13.9%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Fate Therapeutics stock?

Fate Therapeutics (FATE) has a market cap of $596.42M as of April 19, 2024.

What is the P/E ratio for Fate Therapeutics stock?

The price to earnings (P/E) ratio for Fate Therapeutics (FATE) stock is 0 as of April 19, 2024.

Does Fate Therapeutics stock pay dividends?

No, Fate Therapeutics (FATE) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Fate Therapeutics dividend payment date?

Fate Therapeutics (FATE) stock does not pay dividends to its shareholders.

What is the beta indicator for Fate Therapeutics?

Fate Therapeutics (FATE) has a beta rating of 1.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Fate Therapeutics stock price target?

The target price for Fate Therapeutics (FATE) stock is $7.8, which is 61.83% above the current price of $4.82. This is an average based on projections from 15 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Fate Therapeutics stock

Buy or sell Fate Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing